Roger S. Kirby

A selected review and personal experience with robotic prostatectomy: implications for adoption of this new technology in the United Kingdom

Robot-assisted laparoscopic prostatectomy (RALP) is a rapidly evolving technique for the treatment of localized prostate cancer. However, cynics point to the increasing role of market forces in the robotic revolution. As yet, Europe has not taken up RALP in large numbers and this may in part relate to the high level of expertise in laparoscopy previously gained. Furthermore, setting up a robotic programme is a major undertaking for many surgical units. This review discusses some of the challenges in the development of a robotic service drawn from personal experience within the United Kingdom. Furthermore, available data on RALP versus open and laparoscopic approaches are reviewed for surgical and cancer-related outcomes. Preliminary data appear to show an advantage over open prostatectomy with reduced blood loss, decreased pain and early mobilisation and shorter hospital stay. Most intra-institutional studies demonstrate better postoperative continence and potency with RALP; however, this needs to be viewed in the context of a paucity of randomized data available in the literature. There is no definitive data to show an advantage over standard laparoscopic surgery, but the fact that this technique has reached parity with laparoscopy within 5 years is encouraging: with continued experience, the hope is that results will continue to improve.

Diabetes and the urologist: a growing problem

The incidence of diabetes continues to increase dramatically; this incidence is predominantly of the type‐2 form which clusters together with other comorbidities of hypertension and lipid abnormalities, to form the metabolic syndrome. These conditions will have an increasing impact on urological practice, with erectile dysfunction, hypogonadism, voiding difficulties and urinary tract infections all more common in these patients. These symptoms might be the initial presentation of previously undiagnosed diabetes and it is important to recognise this condition early to avoid later complications including end‐stage renal failure.

What is the role of inflammation in the pathogenesis of prostate cancer

1 Herget EJ, Saliken JC, Donnelly BJ, Gray RR, Wiseman D, Brunet G. Transrectal ultrasound-guided biopsy of the prostate: relation between ASA use and bleeding complications. Can Assoc Radiol J 1999; 50 : 173–6 2 Connor SE, Wingate JP. Management of patients treated with aspirin or warfarin and evaluation of haemostasis prior to prostatic biopsy: a survey of current practice amongst radiologists and urologists. Clin Radiol 1999; 54 : 598–603 3 Ala-Opas MY, Gronlund SS. Blood loss in long-term aspirin users undergoing transurethral prostatectomy. Scand J Urol Nephrol 1996; 30 : 203–6 4 Nielsen JD, Holm-Nielsen A, Jespersen J, Vinther CC, Settgast IW, Gram J. The effect of low dose acetylsalicylic acid on bleeding after transurethral prostatectomy – a prospective, randomized double blind, placebocontrolled study. Scan J Urol Nephrol 2000; 34 : 194–8 5 Enver MK, Hoh I, Chinegwundoh FI. The management of aspirin in transurethral prostatectomy: current practice in the UK. Ann R Coll Surg Engl 2006; 88 : 280–3 6 Fijnheer R, Urbanus RT, Nieuwenhuis HK. [Withdrawing the use of acetylsalicylic acid prior to an operation usually not necessary]. Ned Tijdschr Geneeskd 2003; 147 : 21–5 7 Burger W, Chemnitius JM, Kneissl GD, Rucker G. Low-dose aspirin for secondary cardiovascular prevention – cardiovascular risks after its perioperative withdrawal versus bleeding risks with its continuation – review and meta-analysis. J Intern Med 2005; 257 : 399–414 8 Weightman WM, Gibbs NM, Weidmann CR et al. The effect of preoperative aspirin-free interval on red blood cell transfusion requirements in cardiac surgical patients. J Cardiothorac Vasc Anesth 2002; 16 : 54–8

Overcoming the challenges of robot-assisted radical prostatectomy

Robot-assisted radical prostatectomy (RARP) is the most commonly performed robotic procedure worldwide and is firmly established as a standard treatment option for localised prostate cancer. Part of the explanation for the rapid uptake of RARP is the reported gentler learning curve compared with the challenges of laparoscopic radical prostatectomy (LRP). However, robotic surgery is still fraught with potential difficulties and avoiding complications while on the steepest part of the learning curve is critical. Furthermore, as surgeons progress there is a tendency to take on increasingly complex cases, including patients with difficult anatomy and prior surgery, and these cases present a unique challenge. Significant intra-abdominal adhesions may be identified following open surgery, or dense periprostatic inflammation may be encountered following TURP; large prostate gland size and median lobes may alter bladder neck anatomy, making difficult subsequent urethro-vesical anastomosis. Even experienced robotic surgeons will be challenged by salvage RARP. Approaching these problems in a structured manner allows many of the problems to be overcome. We discuss some of the specific techniques to deal with these potential difficulties and highlight ways to avoid making serious mistakes.

Finasteride and doxazosin alone or in combination for the treatment of benign prostatic hyperplasia

Benign prostatic hyperplasia is an increasingly prevalent condition affecting > 50% of men > 65 years of age. Although it is a condition that is unlikely to be life threatening, it can significantly affect quality of life with distressing lower urinary tract symptoms. Increasingly, medical therapy is being used as first-line treatment for men with moderate-to-severe lower urinary tract symptoms. Two main pharmacological classes of drugs are used: 5α-reductase inhibitors and α-1 selective blockers. Both these classes of drugs have shown good tolerability and clinical efficacy. This article examines the potential benefit of the use of combination therapy. In particular, what is the evidence for using doxazosin and finasteride therapy together?

Does robotically assisted radical prostatectomy result in better preservation of erectile function

Accepted for publication 30 March 2006 signaling in SW480 colon cancer cells. Biochem Biophys Res Commun 2005; 328: 227–34 11 Kirby RS, Fitzpatrick JM. How should we advise patients about the chemoprevention of prostate cancer? BJU Int 2005; 96: 231–2 12 Gardner SH, Hawcroft G, Hull MA. Effect of nonsteroidal anti-inflammatory drugs on beta-catenin protein levels and catenin-related transcription in human colorectal cancer cells. Br J Cancer 2004; 91: 153–63

THE ROLE OF BOTULINUM TOXIN IN BENIGN PROSTATIC HYPERPLASIA

1 Bonetti F, Pea M, Martignoni G, Zamboni G. PEC and sugar. Am J Surg Pathol 1992; 16: 307–8 2 Zamboni G, Pea M, Martignoni G et al. Clear cell ‘sugar’ tumour of the pancreas. A novel member of the family of lesions characterised by the presence of perivascular epitheloid cells. Am J Surg Pathol 1996; 20: 722–30 3 Pea M, Bonetti F, Zamboni G et al. Melanocyte-marker-HMB-45 is regularly expressed in angiomyolipoma of the kidney. Pathology 1991; 23: 185–8 4 Bacchi CE, Bonetti F, Pea M, Martignoni G, Gown AM. HMB-45: a review. Appl Immunohistochem 1996; 4: 73–85 5 Eble JN, Amin MB, Young RH. Epitheloid angiomyolipoma of the kidney: a report of five cases with a prominent and diagnostically confusing epitheloid smooth muscle component. Am J Surg Pathol 1997; 21: 1123–30 6 Mai KT, Perkins DG, Collins JP. Epitheloid variant of renal angiomyolipoma. Histopathology 1996; 28: 277–80 7 Cittadini G Jr, Pozzi Mucelli F, Danza FM, Derchi LE, Pozzi Mucelli RS. ‘Aggressive’ renal angiomyolipoma. Acta Radiol 1996; 37: 927–32 8 Orell SR, Langlois SL, Marshall VR. Fine needle aspiration cytology in the diagnosis of solid renal and adrenal masses. Scand J Urol Nephrol 1985; 19: 211–6 9 Delgado R, de Leon Bojorge B, AlboresSaavedra J. Atypical angiomyolipoma of the kidney: a distinct morphologic variant that is easily confused with a variety of malignant neoplasms. Cancer 1998; 83: 1581–92 10 Pea M, Bonetti F, Martignoni G et al. Apparent renal cell carcinoma in tuberous sclerosis are heterogeneous: the identification of malignant epitheloid angiomyolipoma. Am J Surg Pathol 1996; 20: 1149–53

Prostate-specific antigen kinetics and the diagnosis and management of prostate cancer.

PSA is a serum marker that is central to the diagnosis and management of prostate cancer. However, increases in PSA level can be due either to benign prostatic enlargement or to malignant disease, and the quest continues for a more sensitive and specific marker. Recent reports suggest that PSA kinetics (PSA velocity, PSAV; PSA doubling time, PSADT) might improve its performance as a screening test, based on the hypothesis that PSA levels increase faster in malignant disease than in benign pathology. However, the role of PSA kinetics in the diagnosis of prostate cancer remains controversial.

Fact or fiction: What do the benign prostatic hyperplasia data tell us?

Benign prostatic hyperplasia (BPH) is the most common benign neoplasm in men. Our understanding of this condition has improved greatly over the years and recent advances have changed our approach to management. At the end of the 19th century, prostatic enlargement was treated effectively by bilateral orchiectomy. Unsurprisingly, this treatment option never gained widespread popularity. Less than 10 years ago, surgery and watchful waiting were the only considered treatment options for BPH. We now have a number of medical therapies and minimally invasive treatment options available that can effectively manage lower urinary tract symptoms secondary to benign prostatic obstruction. However, with increased choice comes the increased need for clarity in selection and application of these various treatment options. In the current environment of evidence-based clinical practice, awareness and interpretation of data from the numerous studies is paramount. The lessons learned from these trials should be reflected clearly in our practice, with clinical management based on fact, not fiction. In this review, we critically assess the available data and understanding of the management of BPH.